Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 103

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 103
---
 this proxy statement. More specifically, we ask that you support the compensation of our NEOs as disclosed in the Compensation Discussion and Analysis section, the compensation tables and any related material contained in this proxy statement with respect to our executive officers named in the Summary Compensation Table. Because your vote is advisory, it will not be binding on our CHCC or our Board. However, the CHCC and our Board will review the voting results and take them into consideration when making future decisions regarding the compensation of our NEOs.

Our compensation philosophy is designed to align each executive officer’s compensation with our short- and long-term performance and to provide the compensation and incentives needed to attract, motivate and retain key executive officers who are crucial to our long-term success. Consistent with this philosophy, a significant portion of the total compensation opportunity for each of our NEOs is directly related to performance factors that measure our progress against the goals of our strategic and operating plans, as well as our performance against that of our peer companies.

Stockholders are urged to read the Compensation Discussion and Analysis section of this proxy statement, which discusses how our compensation policies and procedures implement our compensation philosophy. The CHCC and the Board believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals .

As discussed in the Compensation Discussion and Analysis section, we believe the compensation paid to our President and Chief Executive Officer and other NEOs is appropriate as supported by our performance in the year ending December 31, 2024. During fiscal year 2024, we continued to make progress on our strategic growth plan. Some of our most notable business achievements during fiscal year 2024 include:

• Our revenues increased 11% from the year ended December 31, 2023, to $838 million.

• Our revenue growth was driven by Pharmacogenomics revenue growth of 23% year-over-year as well as Prenatal and Hereditary Cancer revenue growth year-over-year of 17% and 11%, respectively.

• Acquired select assets from Intermountain Precision Genomics' laboratory business, including the Precise Tumor test, the Precise Liquid test, and a CLIA-certified laboratory.

• Ranked among Best Large Workplaces in Health Care by Fortune and achieved a Great Place to Work ® Certification for 2024.

• Completed the reorganization of our international operations, which included a sale of our EndoPredict business to Eurobio Scientific, enabling us to better align our resources to our domestic opportunities while continuing to serve key biopharma partners and patients